Tests a personalized lifestyle program for older adults at risk of memory decline
Tests a tailored lifestyle program in adults aged 55 to 75 with memory decline concerns.
Plain-language title generated from the registry record
Registry title: LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment.
Key facts
- Where
- Graz, Innsbruck, and Vienna, AustriaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 75 who worry about their memory or have a parent, brother or sister with dementia, but whose thinking tests are still near normal.
- Age
- 55 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Memory or thinking has declined in the person's own view, and/or a parent, brother or sister has dementia. Thinking tests must be near normal: m-TICS score of 37/50 or more and MoCA score of 26/30 or more.
- Earlier treatment
- Cannot join if currently using or ever used Alzheimer's or other dementia medication.
Main reasons for not taking part
- Diagnosed or suspected dementia, or m-TICS score of 36 or less, or MoCA score below 26
- Serious brain or nerve disease such as Parkinson's disease, multiple sclerosis or brain tumour
- Severe problems with vision, hearing or communication
- Active cancer, major depression, heart disease with symptoms, or heart procedure in the past year
- Taking part in another interventional trial that interferes with this one
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
- Has a doctor told you that you have Alzheimer's disease?
Source: NCT07376135, who can take part
Where in Austria
- Medical University of InnsbruckGraz, AustriaNo longer taking part
- Medical University of InnsbruckInnsbruck, AustriaNo longer taking part
- Medical University of ViennaVienna, AustriaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT07376135
- Record updated
- 29 January 2026
- Original description
The goal of this clinical trial is to learn whether a hybrid multidomain lifestyle program can prevent cognitive decline and reduce dementia risk in community-dwelling adults in mid- to late life who are at increased risk of Alzheimer´s disease or related dementias but do not yet have significant cognitive impairment.Read full original descriptionShow less
Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults - the LETHE-AT Randomised-controlled, Multicentre Pilot Trial
The goal of this clinical trial is to learn whether a hybrid multidomain lifestyle program can prevent cognitive decline and reduce dementia risk in community-dwelling adults in mid- to late life who are at increased risk of Alzheimer´s disease or related dementias but do not yet have significant cognitive impairment.
The main question the study aims to answer are:
* Whether the structured hybrid multidomain lifestyle intervention is feasible (e.g., adherence and retention rate), and how well the digital components are accepted and implemented in the intervention group. * Does the intervention reduces the overall burden of modifiable dementia risk factors and improves global cognitive performance compared with usual care.
Researchers will compare participants assigned to the tailored hybrid multidomain lifestyle intervention group with those in a self-guided multimodal lifestyle advice group.
Participants assigned to the intervention group will receive a plan adjusted to their individual dementia risk profile. A physician trained in motivational interviewing will review their progress continuously.
The self-guided multimodal lifestyle advice group will receive rigid but comprehensible lifestyle health advice with reduced access to digital support tools.
Participants will:
* Complete an initial risk assessment that uses machine-learning triage to identify and prioritize their most important modifiable dementia risk factors. * Receive personalized recommendations for gradual lifestyle change, including physical activity, nutrition, cognitive training, other dementia risk-factor management (e.g. hearing impairment), stress \& sleep management, and social activities. * Use a smartphone and smartwatch to passively collect digital biomarkers and to complete questionnaires at regular intervals, so that physicians trained in motivational interviewing can adapt goals through shared decision making. * Use a study app as the central access point for the program, including educational content, progress tracking, and gamified challenges with social comparison and incentives.
Inclusion: Age between 55 and 75 years at the time of screening; Fluency in German; All participants must be able and willing to provide written informed consent form (ICF) prior to any study-related procedures; Ownership of a compatible Android smartphone, or willingness and capability to use a study-provided Android smartphone for the duration of the study; Subjective cognitive decline and/or a positive first-degree family history of dementia; Willingness to make meaningful changes in at least three of six lifestyle domains: dietary counselling, physical activity, cognitive training, vascular risk management, social interaction, and sleep and relaxation; Cognitive performance at or slightly below age expectations, defined as an m-TICS (modified Telephone Interview for Cognitive Status) score ≥ 37/50, and a Montreal Cognitive Assessment (MoCA) ≥ 26/30.
Exclusion: Diagnosed or suspected dementia or substantial cognitive impairment, defined as an m-TICS score ≤ 36 or MoCA < 26, or current or previous use of Alzheimer´s disease or other dementia medication; Significant neurological disease, including but not limited to Parkinson´s disease, Huntington´s disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis, or a history of significant head trauma with persistent neurological sequelae or known structural brain abnormalities; Diminished decision-making capacity, inability to provide informed consent, inability to complete study assessments, or any condition preventing effective cooperation, as determined by clinical judgement; Severe impairment of vision, hearing, or communication abilities that would preclude participation in study procedure; Any medical or psychiatric condition affecting safe engagement, including but not limited to active malignancy, major depressive disorder, symptomatic cardiovascular disease, or revascularisation procedures within the past year; Current participation in another interventional trial, unless the study team determines this does not interfere with participation in the LETHE-AT.